Spikevax (previously COVID-19 Vaccine Moderna)
WEBJan 6, 2021 · Spikevax JN.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with official recommendations.
Spikevax (COVID-19 Vaccine, mRNA) 2024-2025 Formula - Moderna
WEBLearn about Moderna's Spikevax® (COVID-19 Vaccine, mRNA) 2024-2025 Formula and how it helps protect against emerging variants, following ACIP recommendation.
First adapted COVID-19 booster vaccines recommended for …
WEBSep 1, 2022 · The study found that a booster dose of Spikevax bivalent Original/Omicron BA.1 induced a stronger immune response against the SARS-CoV-2 strain and the Omicron subvariant BA.1 compared with a booster dose of the original Spikevax vaccine.
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
WEBSep 16, 2022 · We previously reported that a modified, bivalent booster vaccine 20 containing equal amounts of messenger RNAs (mRNAs) encoding the ancestral SARS-CoV-2 and beta variant spike proteins elicited...
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA …
WEBJul 25, 2023 · A fourth dose with a bivalent BA.1 booster was similarly associated with lower risks of admission to hospital with covid-19 (332 v 977 events), corresponding to a comparative vaccine effectiveness of 65.8% (59.1% to 72.4%) and a risk difference of –112.9 (–179.6 to –46.2) per 100 000 people.
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines ... - The BMJ
WEBJul 25, 2023 · Bivalent mRNA booster doses with either the Pfizer-BioNTech vaccine Comirnaty (BNT162b2, original strain and omicron variant BA.4-5 or BA.1), or the Moderna vaccine Spikevax (mRNA-1273, original and BA.1) that target the original (ancestral) strain of SARS-CoV-2 and omicron variant BA.4-5 or BA.1, were authorised for use in early autumn 2022.1 ...
Omicron BA.1-containing mRNA-1273 boosters compared with …
WEBJun 19, 2023 · Monovalent mRNA-1273 (Spikevax, Moderna, Cambridge, MA, USA) and omicron BA.1 vaccines contain single mRNAs (50 μg) encoding the prefusion-stabilised spike glycoprotein of ancestral SARS-CoV-2 (Wuhan …
Spikevax: EMA recommends approval of adapted COVID-19 …
WEBSep 14, 2023 · EMA’s human medicines committee (CHMP) has recommended authorising an adapted Spikevax vaccine targeting the Omicron XBB.1.5 subvariant. The vaccine — known as Spikevax XBB.1.5 — is to be used for preventing COVID-19 in adults and children from 6 months of age.
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults …
WEBJan 18, 2023 · The bivalent vaccine contains equal amounts of ancestral spike mRNA and omicron BA.1 spike mRNA coformulated into lipid nanoparticles.
WEBSPIKEVAX is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in...